SG150550A1 - Pharmaceutical preparation containing an antibody for the egf receptor - Google Patents
Pharmaceutical preparation containing an antibody for the egf receptorInfo
- Publication number
- SG150550A1 SG150550A1 SG200901382-2A SG2009013822A SG150550A1 SG 150550 A1 SG150550 A1 SG 150550A1 SG 2009013822 A SG2009013822 A SG 2009013822A SG 150550 A1 SG150550 A1 SG 150550A1
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- pharmaceutical preparation
- egf receptor
- preparation containing
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10355251A DE10355251A1 (de) | 2003-11-26 | 2003-11-26 | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG150550A1 true SG150550A1 (en) | 2009-03-30 |
Family
ID=34609304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200901382-2A SG150550A1 (en) | 2003-11-26 | 2004-10-26 | Pharmaceutical preparation containing an antibody for the egf receptor |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20050175611A1 (ja) |
| EP (1) | EP1687031B1 (ja) |
| JP (1) | JP2007512266A (ja) |
| KR (1) | KR20060110305A (ja) |
| CN (1) | CN1886158B (ja) |
| AR (1) | AR047949A1 (ja) |
| AT (1) | ATE457740T1 (ja) |
| AU (1) | AU2004298728B2 (ja) |
| BR (1) | BRPI0416986A (ja) |
| CA (1) | CA2547060A1 (ja) |
| CO (1) | CO5690620A2 (ja) |
| CY (1) | CY1110344T1 (ja) |
| DE (2) | DE10355251A1 (ja) |
| DK (1) | DK1687031T3 (ja) |
| EC (1) | ECSP066662A (ja) |
| ES (1) | ES2339671T3 (ja) |
| HK (1) | HK1095534A1 (ja) |
| IL (1) | IL175727A0 (ja) |
| MX (1) | MXPA06005901A (ja) |
| MY (1) | MY145214A (ja) |
| NZ (1) | NZ548129A (ja) |
| PE (1) | PE20050586A1 (ja) |
| PL (1) | PL1687031T3 (ja) |
| PT (1) | PT1687031E (ja) |
| RU (1) | RU2381036C2 (ja) |
| SG (1) | SG150550A1 (ja) |
| SI (1) | SI1687031T1 (ja) |
| TW (1) | TWI322693B (ja) |
| UA (1) | UA90460C2 (ja) |
| WO (1) | WO2005058365A1 (ja) |
| ZA (1) | ZA200605219B (ja) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8212004B2 (en) * | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| PT2275449T (pt) | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| KR20140077946A (ko) * | 2005-10-13 | 2014-06-24 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
| WO2007123765A2 (en) * | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| MEP39508A (en) * | 2006-04-21 | 2011-02-10 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
| EP2094247B1 (en) * | 2006-10-20 | 2022-06-29 | Amgen Inc. | Stable polypeptide formulations |
| WO2008079818A2 (en) * | 2006-12-21 | 2008-07-03 | Soluprin Pharmaceuticals, Inc. | Intravenous administration of water soluble analgesic formulations |
| US20090181027A1 (en) * | 2007-09-28 | 2009-07-16 | Paul Dal Monte | Anti-IL-12/23p40 Antibodies, Epitopes, Formulations, Compositions, Methods and Uses |
| KR20090056543A (ko) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제 |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN101716343A (zh) * | 2008-10-09 | 2010-06-02 | 哈药集团生物工程有限公司 | 一种单克隆抗体的冻干制剂 |
| CN101797383A (zh) * | 2009-02-05 | 2010-08-11 | 哈药集团生物工程有限公司 | 一种单克隆抗体的水针制剂 |
| EP2396035A4 (en) * | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE |
| RU2560701C2 (ru) * | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
| US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| US20120294866A1 (en) * | 2010-01-19 | 2012-11-22 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for proteins |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| BR112013031906A2 (pt) * | 2011-06-16 | 2016-12-13 | Dsm Ip Assets Bv | unidade única de cromatografia de purificação de anticorpo |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| MX354988B (es) | 2011-10-25 | 2018-03-28 | Prothena Biosciences Ltd | Formulaciones de anticuerpo y metodos. |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
| MX360107B (es) | 2012-11-13 | 2018-10-23 | Adocia | Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido. |
| EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| FR3020947B1 (fr) * | 2014-05-14 | 2018-08-31 | Adocia | Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| CA2995645A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| FR3043557B1 (fr) | 2015-11-16 | 2019-05-31 | Adocia | Composition a action rapide d'insuline comprenant un citrate substitue |
| CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
| US20210322554A1 (en) * | 2018-09-10 | 2021-10-21 | Dow Global Technologies Llc | A composition comprising a protein and a polyalkoxy fatty acyl surfactant |
| CN110960490A (zh) * | 2018-09-28 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种抗egfr抗体偶联药物组合物及其用途 |
| WO2020104943A2 (en) | 2018-11-20 | 2020-05-28 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il-23 specific antibody |
| US20230287122A1 (en) * | 2018-11-29 | 2023-09-14 | Harbour Biomed Therapeutics Limited | Anti-pd-l1 antibody preparation |
| CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
| JP2022534020A (ja) | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
| JPWO2022230390A1 (ja) * | 2021-04-27 | 2022-11-03 | ||
| CN115300623A (zh) * | 2021-05-08 | 2022-11-08 | 盛禾(中国)生物制药有限公司 | 抗egfr融合蛋白或其抗原结合片段的组合物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11510170A (ja) * | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| KR20030074693A (ko) * | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| DE10133394A1 (de) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Flüssige Formulierung enthaltend Cetuximab |
| DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
| WO2004060343A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics | Antibody-containing particles and compositions |
-
2003
- 2003-11-26 DE DE10355251A patent/DE10355251A1/de not_active Withdrawn
-
2004
- 2004-10-26 SG SG200901382-2A patent/SG150550A1/en unknown
- 2004-10-26 PT PT04820387T patent/PT1687031E/pt unknown
- 2004-10-26 PL PL04820387T patent/PL1687031T3/pl unknown
- 2004-10-26 AU AU2004298728A patent/AU2004298728B2/en not_active Ceased
- 2004-10-26 CN CN2004800347064A patent/CN1886158B/zh not_active Expired - Fee Related
- 2004-10-26 SI SI200431369T patent/SI1687031T1/sl unknown
- 2004-10-26 DK DK04820387.1T patent/DK1687031T3/da active
- 2004-10-26 AT AT04820387T patent/ATE457740T1/de active
- 2004-10-26 EP EP04820387A patent/EP1687031B1/de not_active Revoked
- 2004-10-26 DE DE502004010783T patent/DE502004010783D1/de active Active
- 2004-10-26 KR KR1020067010225A patent/KR20060110305A/ko not_active Application Discontinuation
- 2004-10-26 MX MXPA06005901A patent/MXPA06005901A/es active IP Right Grant
- 2004-10-26 RU RU2006122638/15A patent/RU2381036C2/ru not_active IP Right Cessation
- 2004-10-26 ES ES04820387T patent/ES2339671T3/es active Active
- 2004-10-26 UA UAA200607106A patent/UA90460C2/ru unknown
- 2004-10-26 BR BRPI0416986-7A patent/BRPI0416986A/pt not_active IP Right Cessation
- 2004-10-26 NZ NZ548129A patent/NZ548129A/en not_active IP Right Cessation
- 2004-10-26 CA CA002547060A patent/CA2547060A1/en not_active Abandoned
- 2004-10-26 JP JP2006540214A patent/JP2007512266A/ja active Pending
- 2004-10-26 WO PCT/EP2004/012044 patent/WO2005058365A1/de active Application Filing
- 2004-11-22 MY MYPI20044833A patent/MY145214A/en unknown
- 2004-11-24 PE PE2004001152A patent/PE20050586A1/es not_active Application Discontinuation
- 2004-11-25 TW TW093136361A patent/TWI322693B/zh not_active IP Right Cessation
- 2004-11-26 AR ARP040104380A patent/AR047949A1/es not_active Application Discontinuation
- 2004-11-26 US US10/996,597 patent/US20050175611A1/en not_active Abandoned
-
2006
- 2006-05-17 IL IL175727A patent/IL175727A0/en unknown
- 2006-05-24 CO CO06050041A patent/CO5690620A2/es not_active Application Discontinuation
- 2006-06-21 EC EC2006006662A patent/ECSP066662A/es unknown
- 2006-06-23 ZA ZA200605219A patent/ZA200605219B/en unknown
-
2007
- 2007-03-13 HK HK07102712.6A patent/HK1095534A1/xx not_active IP Right Cessation
-
2010
- 2010-05-13 CY CY20101100415T patent/CY1110344T1/el unknown
-
2011
- 2011-03-24 US US13/070,952 patent/US20110177068A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG150550A1 (en) | Pharmaceutical preparation containing an antibody for the egf receptor | |
| IL273422A (en) | Methods and systems for extracorporeal organ treatment | |
| RS20060320A (en) | Substituted indazole-o-glucosides | |
| MY142777A (en) | Substituted indole-o-glucosides | |
| UA86042C2 (en) | Substituted indazole-o-glucosides | |
| MY137181A (en) | Pulmonary administration of chemically modified insulin | |
| MY136764A (en) | Indole-3-carboxamides as glucokinase (gk) activators | |
| RS93604A (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| TW200716646A (en) | (S)-N-methylnaltrexone | |
| IL190796A (en) | Composition containing nucleic acid encoded by anti-osteoclastogenic protein | |
| IL195338A0 (en) | Optimized fc variants and methods for their generation | |
| DE60111570D1 (de) | Isoindolin-1-on als glukokinaseaktivatoren | |
| BRPI0507680A (pt) | partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas | |
| BR0215266A (pt) | Preparação liofilizada compreendendo anticorpos contra o receptor de egf | |
| ZA200606620B (en) | Methods of modulating IL-23 activity ; related reagents | |
| TW200624426A (en) | BACE inhibitors | |
| IL171974A0 (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
| BR0208741A (pt) | Derivados de piperidina | |
| TW200800967A (en) | Benzimidazole thiophene compounds | |
| MXPA05002489A (es) | Composiciones para el cuidado personal basadas en alcohol ramificado. | |
| EA200870058A1 (ru) | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран | |
| IN2012DN03844A (ja) | ||
| UA106200C2 (uk) | Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину | |
| DK1411971T3 (da) | Anvendelse af lang gentraxin PTX3 til behandling af kvindelig sterilitet | |
| PL1912954T3 (pl) | Nowe inhibitory proteaz cysteinowych i ich terapeutyczne zastosowania |